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The intrapartum prevention of group B streptococcus (GBS) bacterial infection in the newborn is based
on Centers for Disease Control and Prevention (CDC) guidelines published1 in 2002 that require
universal antepartum screening. An antepartum culture is to be obtained between 35 to 37 weeks'
gestation from the vaginal to rectal area; the culture can be safely obtained by the woman herself.
Vaginal cultures alone yield only 60% of the GBS identified, compared to those taken from both the
vagina and rectum,2hence the guidelines require sampling from both areas. The CDC guidelines require
intrapartum antibiotic prophylaxis (IAP) to be delivered intravenously by the nursing staff if the
woman's culture is positive for GBS or if she has a preexisting risk factor that would indicate the need

for IAP without testing for the presence of GBS colonization. Intrapartum antibiotic prophylaxis was
based on 5 controlled trials that support efficacy of the approach in reducing neonatal GBS infection.3
The guidelines were specifically intended to reduce the rate of early onset group B streptococcus
(EOGBS) disease, which is associated with significant newborn mortality and morbidity with profound
sequelae. Early onset group B streptococcus infections occur in the first week of life; prevention has
presented a major challenge in perinatal nursing practice. When neonatal EOGBS disease occurs, it has
a 5% to 10% mortality rate.4 The implementation of the 2002 CDC guidelines1 has reduced the overall
incidence of invasive neonatal EOGBS infection. For example, in one study5 that included 5 states, the
rates of EOGBS declined from 0.47 cases per 1000 live births in 1999–2001 to 0.34 cases from 2003–
2005, which amounts to a 27% reduction. Compared to a decade earlier, when the rate in 1993 was
reported to be 1.7 cases per 1000 live births, the decreased incidence of EOGBS disease is even more
evident. To further reduce EOGBS disease, adherence to the GBS guidelines based on antepartum test
results, with IAP given to appropriate candidates, has important risk management considerations. It
was estimated that timely administration of IAP could prevent as much as 80% of perinatal GBS
infections.6 A portion of the EOGBS residual infections may be related to the approximately 4% of
women with false-negative cultures during the third trimester.7Another smaller portion of the EOGBS
infections could be due to nonadherence to the GBS guidelines.8

SOURCE OF GBS
Early onset group B streptococcus infections are almost exclusively the result of vertical transmission
from the mother.9 Fully, 80% of all the neonatal GBS infections1 are early onset and associated with a
significant portion of the GBS-related mortality.4 (Late onset GBS disease, defined as occurring from 1
week up to 3 months (89 days) after birth, is differentiated as a separate entity, is not addressed in the
CDC guidelines,1 and is beyond the scope of this article.)
Independent of hygiene, most vaginal bacteria originate and ascend from intestinal microbes.10 Group
B streptococcus is normal flora present in the gastrointestinal track and vaginas of 10% to 30% of
women. Variation is noted by ethnicity, with African American women having higher rates of GBSpositive cultures (up to 40.6%) and heavier colonization than women of other ethnic groups.11 Heavier
colonization is directly related to the risk of giving birth to a GBS-colonized infant.11 Group B
streptococcus colonization may be transient, intermittent, or chronic.1,12 In healthy pregnant women,
this normal flora may be vertically transmitted to infants during birth and lead to EOGBS infections
even if the amniotic membranes are intact.13 Of colonized women, it is estimated that the rate of
maternal-neonatal transmission is 1% to 2%, with 3% to 12% of neonates developing bacteremia
resulting in EOGBS disease.4

INTRAPARTUM ANTIBIOTIC PROPHYLAXIS
On the basis of the population incidence of colonization, the universal testing approach potentially
results in IAP exposure for 10% to 40% of laboring women. Penicillin (PCN) G is the preferred antibiotic
for IAP; ampicillin can be used to replace PCN, but not if the woman has a PCN allergy. Alternative
antibiotic selection is based on a history of allergies and GBS susceptibility to various antibiotic agents.
The other medications that can be substituted in particular situations are erythromycin, clindamycin,
cefazolin, or vancomycin. For women with PCN allergies who are at low risk of anaphylaxis, cefazolin is

the recommended IAP agent.6 If the PCN-allergic woman's culture results indicate resistance or
susceptibility is unknown, vancomycin is indicated.6
Antibiotic resistance is a growing concern especially for PCN-allergic women.6 Thus far, a less than 2%
resistance to PCN has been reported.14 However, 2 of the substitutes for PCN-allergic women,
erythromycin and clindamycin, are increasingly associated with GBS resistance.6,15 Therefore, routine
testing for antibiotic susceptibility is recommended when women are not PCN
candidates.16,17 Regardless of the chosen medication for IAP, nursing responsibilities include
monitoring for allergic reactions to the agent administered.
According to the 2002 CDC guidelines,1 optimal prophylaxis is 4 hours prior to birth.6 If labor continues
beyond that point, the guidelines direct that IAP be repeated every 4 hours. Several studies have
shown that the 4-hour time frame was not scientifically determined. Colombo and
colleagues18 examined 21 women with scheduled cesarean sections who received intravenous
ampicillin before delivery and agreed to simultaneous blood sampling when the newborn cord blood
was drawn at birth. The shortest IAP to birth time was 27 minutes; by that time, the bactericidal level
in the cord blood was adequate. The bactericidal levels continued to increase in a linear relationship up
to 5.6 hours following dosing, which was the longest interval to delivery in the study.18 Illuzzi and
Bracken19 conducted a systematic review of 4 studies and found that the incidence of GBS-colonized
neonates born to GBS-positive mothers decreased substantially within 1 to 2 hours of IAP. The authors
added that the pharmacokinetic data did not support the rationale for the 4-hour time frame. Bloom
and associates20 documented that bactericidal concentrations of ampicillin in fetal and maternal blood
were reached within 3 minutes and in amniotic fluid within 5 minutes during elective cesarean
sections. Thus, invasive newborn testing and separation from mothers for extended observations may
not be indicated when IAP was administered less than 4 hours prior to birth.

CONTINUED CHALLENGES
While IAP for women colonized with GBS has successfully reduced the incidence of EOGBS, it is not
without consequences. The 2002 CDC guidelines1 include treatment of GBS-positive women with IAP;
however, the problem of neonatal EOGBS infections has not been eradicated.
Mortality is significantly higher in preterm infants, with prematurity accounting for two thirds of all
GBS-related deaths.4 Therefore, a woman who is in active preterm labor with an unknown GBS status,
and expected to deliver preterm, should receive IAP. Given that women with a late preterm infant do
not commonly receive tocolytic agents and the course of labor may be rapid, there is a risk that GBS
prevention may not occur.
Group B streptococcus can be identified on routine urine cultures done any time during pregnancy. The
incidence of antenatal GBS bacteriuria is estimated9 at 2% to 4%. Prompt treatment of the urinary tract
infection following diagnosis is necessary. Group B streptococcus cultures during the third trimester
are not indicated for women affected with GBS bacteriuria; they are considered heavier colonizers of
GBS and require IAP because their infants are at greater risk of EOGBS infections.1 The same holds true
for a woman who has given birth previously to an infant with an invasive GBS infection. These mothers
are also considered heavier colonizers and therefore at high risk of transmitting GBS to subsequent
neonates; they are to receive IAP without the need for antepartal culturing.1

The intrapartum care of a woman with unknown GBS status presents an additional challenge for nurses
and other healthcare providers. When the GBS status is unknown, the woman should be treated using
a risk-based approach.1 When a culture was not obtained prenatally or the result is unknown, women
who have one of the following risk factors should receive IAP: (1) less than 37 weeks' gestation with
anticipation of delivery, (2) rupture of membranes greater than or equal to 18 hours, and (3) maternal
temperature greater than or equal to 100.4°F. Women who have unknown GBS status without any risk
factors should not receive IAP. Conversely, IAP is not indicated when women have a negative GBS
culture in the third trimester, even if an intrapartum risk factor develops.1

ONGOING NEONATAL CONCERNS
The symptoms of EOGBS include respiratory instability, apnea, lethargy, and hypotension.21 These
symptoms manifest quickly. For example, a study of 277 912 live births identified 172 infants with
positive GBS cultures and clinical signs of EOGBS infection. Of these, 95% were symptomatic within 24
hours, another 3.7% within 48 hours, with only 1.2% demonstrating symptoms after 48
hours.22 Therefore, the vast majority of EOGBS infections will be detectible within one day of life.22 In
affected neonates, bacteremia, meningitis, and pneumonia may result. Approximately, 5% of neonatal
bacteremia is thought to be nosocomial in origin,4 highlighting the nursing responsibility of careful
hand washing during client care.
While IAP is protective, it is not without neonatal consequences. Ampicillin is a broad spectrum
antibiotic, and therefore is more likely to lead to problems with antibiotic resistance. Although data are
based on a small number of cases, the incidence of Escherichia coli bacteremia appears to have
increased, especially in very low-birth-weight neonates.4 This may be attributable to ampicillin
resistant E coli strains, but evidence linking it specifically to IAP is lacking.4 Intrauterine exposure to
broad spectrum antibiotics may alter the neonatal gut flora in ways that might have long-term effects
and could be related to the development of allergic sensitivity.23

CLINICAL IMPLICATIONS
Pinto and colleagues24 speculated about multiple causes of residual cases of EOGBS infections despite
the use of the CDC guidelines.1 These included confusion about existing guidelines, lack of access to
GBS culture results on admission, rapid labor progress, and maternal refusal of IAP. Knowledgeable
perinatal nurses can impact the first two issues and use careful documentation to explain the lack of
IAP for the latter two.
Several strategies can improve adherence to the CDC guidelines1 and therefore reduce residual cases
of EOGBS. For example, preprinted orders can streamline the initiation of IAP. The intrapartum nurse
needs to locate the culture result and also confirm when the specimen was collected. Group B
streptococcus culture results taken 6 weeks or more prior to birth have only a 43% sensitivity and a
85% specificity. This is contrasted with cultures taken between 1 to 5 weeks prior to delivery that have
a 87% sensitivity and a 96% specificity.7
Adherence to the 2002 CDC guidelines1 has resulted in a significant decrease in EOGBS infections. One
concern for women and nurses is the timing of IAP. Penicillin and ampicillin are the only recommended
antibiotics that require redosing every 4 hours until birth. On the basis of the studies of ampicillin

administration that identified that bacteriocidal levels were rapidly achieved in both the mother and
fetus following IAP, a woman can be reassured that she is likely adequately prophylaxed prior to the 4hour time frame suggested in the guidelines.18 Further, if there is a delay in administering a repeat IAP
dose, Colombo and colleagues18 documented bactericidal concentrations up to 5.6 hours post-IAP. The
antibiotics appropriate for PCN-allergic women are given every 6 to 12 hours, depending on the agent
used.1 This knowledge can be shared with women. Because women can become ill with
chorioamnionitis, endometritis, postpartum wound infections, and septicemia as a result of GBS,25 IAP
also may avert serious maternal infections.

FUTURE DIRECTIONS
Nurses need to remain current as guidelines and diagnostics change. For example, a rapid GBS test
done during intrapartum care may improve detection of GBS colonization at the time of birth.8 A
maternal GBS vaccine is in development but far from use in the general population.26 While it is true
that in the future GBS management may change, lack of adherence to the current prevention
guidelines is not optional.
Creative approaches are needed to further eliminate the incidence, and the profound consequences,
of residual cases of neonatal EOGBS disease. Despite the successes attributable to the current
guidelines, the amount of treatment required and the related costs cannot be ignored. Furthermore,
the long-term consequences of IAP, including repeated dosing, for women and infants have not been
documented. The use of IAP alters normal birth for almost one third of all women. Just the necessity of
an intravenous catheter can create an atmosphere that medicalizes the experience. In addition,
parents worry about GBS throughout late pregnancy and birth, particularly in terms of the timing of
their entry into the birth environment to receive IAP. The parents' emotional issues associated with
GBS colonization warrant investigation. Facilitating IAP in an out-of-hospital birth setting adds
technologic complexity. For example, home birth practitioners must transport the necessary
equipment and supplies. The cumulative impact of GBS colonization on normal birth processes needs
investigation. These authors plan to explore the impact of probiotics on GBS colonization in pregnant
women. It is hoped that the prenatal use of probiotics will alter the maternal gut and vaginal flora to
reduce the incidence of GBS colonization in late pregnancy.
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